The Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality Improvement InitiativeMolly Miloslavsky, MD, a, b Marjorie F. Galler, MD, a Iman Moawad, PharmD, c Janet Actis, RN, d Brian M. Cummings, MD, a, e Chadi M. El Saleeby, MDa, b, f

Departments of aPediatrics, cPharmacy, and dNursing, and Divisions of bHospital Medicine, eCritical Care, and fInfectious Diseases, Massachusetts General Hospital for Children, Harvard Medical School, Boston, Massachusetts

Dr Miloslavsky participated in study design and implementation, data collection, data analysis, and drafting and revision of the manuscript; Dr Galler participated in study implementation, data collection and drafting and revision of the manuscript; Dr Moawad conceptualized the study, participated in its design, implementation, and in data collection, and revised the manuscript; Ms Actis contributed to implementation of the study and dissemination of the guidelines, participated in data collection, and revised the manuscript; Dr Cummings participated in data analysis, completed the quality improvement statistics, and revised the manuscript; Dr El Saleeby supervised the project, participated in study design and implementation, completed the standard statistical analysis, and revised the manuscript; and all authors reviewed and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

DOI: https:// doi. org/ 10. 1542/ peds. 2016- 2423

Accepted for publication Feb 2, 2017

Address correspondence to Chadi M. El Saleeby, MD, Department of Pediatrics, Massachusetts General Hospital for Children, 175 Cambridge St, Boston, MA 02114. E-mail: celsaleeby@mgh.harvard.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2017 by the American Academy of Pediatrics

Vancomycin is an antibiotic commonly used to treat Gram-positive infections in hospitalized patients, particularly infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The most recent American Society of Health-System Pharmacists (ASHP) and Infectious Diseases Society of America (IDSA) consensus guidelines suggest a goal trough of 15 to 20 µg/mL in serious or invasive infections, significantly higher than

previously used, to enhance treatment efficacy and decrease antibiotic resistance.1, 2 These higher troughs are generally used as a surrogate marker to target an area under the curve/minimum inhibitory concentration (AUC/MIC) ratio of ≥400, which has been shown to correlate with improved clinical effectiveness in patients infected with S. aureus with an MIC ≤ 1 mg/L.1 To achieve this trough goal, the dose recommended

abstractBACKGROUND AND OBJECTIVES: There are limited data guiding vancomycin dosing practices in the pediatric population to target the goal troughs recommended by national vancomycin guidelines. In this study, we sought to improve adherence to guideline trough targets through a quality improvement intervention.METHODS: A retrospective analysis was first conducted to assess baseline performance. A multidisciplinary team then developed and implemented a standardized dosing algorithm recommending 15 mg/kg per dose for mild and moderate infections (goal trough: 10–15 µg/mL) and 20 mg/kg per dose for severe infections (goal trough: 15–20 µg/mL), both delivered every 6 hours (maximum single dose: 750 mg). The impact of the intervention was evaluated prospectively using standard statistics and quality improvement methodology. The outcome measures included the percentage of patients with an initial therapeutic trough and the time to therapeutic trough.RESULTS: A total of 116 patients (49 preintervention, 67 postintervention) were included. Postintervention, there was a significant increase in the percentage of patients with an initial therapeutic trough (6.1% to 20.9%, P = .03) and in the percentage of patients with initial troughs between 10 and 20 µg/mL (8.2% to 40.3%, P < .001). The time to therapeutic trough decreased from 2.78 to 1.56 days (P = .001), with the process control chart showing improved control postintervention. Vancomycin-related toxicity was unchanged by the intervention (6.1% versus 4.5%; P = .70).CONCLUSIONS: Using quality improvement methodology with standardized higher initial vancomycin doses, we demonstrated improved adherence to national trough guidelines without noted safety detriment.

QUALITY REPORTPEDIATRICS Volume 139, number 6, June 2017:e20162423

To cite: Miloslavsky M, Galler MF, Moawad I, et al. The Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality Improvement Initiative. Pediatrics. 2017;139(6):e20162423

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

MIlOSlAVSky et al

was 15 mg/kg every 6 hours for pediatric patients.2 It is unclear, however, if the high trough goal can be reliably attained by using the suggested dosing3, 4 and if the use of higher doses will improve target attainment within a clinically appropriate time interval.

Similar to previous reports, 3 – 5 we have observed disparate and inconsistent dosing practices at our institution as well as frequent subtherapeutic initial troughs and lengthy time intervals for patients to reach therapeutic levels. For many prescribers, the fear of causing renal damage may overshadow the concern for underdosing of patients.

Consequently, we conducted a quality improvement (QI) project to optimize vancomycin practices at our institution in line with national guidelines. Our specific aims were threefold: (1) study which vancomycin doses would more reliably lead to desired troughs; (2) based on this information, develop new standardized dosing guidelines for pediatric patients; and (3) improve adherence to the IDSA/ASHP recommended trough goals through the application of the new guidelines.

MeThODs

A multidisciplinary team comprised of 3 physicians, an attending nurse, and a pediatric pharmacist was assembled to conduct this QI project. The study consisted of 3 phases: (1) a baseline diagnostic chart review; (2) development, approval, and implementation of standardized pediatric vancomycin dosing guidelines; and (3) postintervention prospective monitoring and data analysis. This project was undertaken as a QI initiative and, as such, was not formally supervised by the institutional review board per its policies.

Phase 1: Diagnostic Data and Baseline Performance

In phase 1, we performed a retrospective chart review to evaluate vancomycin prescribing practices at our institution and to determine the relationship between the initial dose used and the resultant trough. Over a 4-year period (2010 to 2013), patients who were 1 month to 18 years old, admitted to the pediatric floors or the PICU, treated with at least 3 similar and uninterrupted doses of vancomycin, and who had an appropriately timed trough obtained at steady-state (defined as within 1 hour before the fourth or fifth dose) were included. Patients were excluded if they had an acute kidney injury, chronic kidney disease or renal transplant, cystic fibrosis, or if they were on vasopressors for cardiovascular instability, or aminoglycoside therapy while being treated with vancomycin. The abstracted data included patient demographics, medical history, presumptive and confirmed diagnosis, details of each vancomycin dose and frequency, serum vancomycin trough levels, serum creatinine levels if obtained, concomitant use of nonsteroidal antiinflammatory agents, intravenous contrast, or aminoglycoside antibiotics, as well as all-cause adverse events. Nephrotoxicity was defined as ≥2 consecutive serum creatinine levels of 0.5 mg/dL above the patient’s baseline or ≥50% of the patient’s baseline, whichever was greater.1

Mild to moderate infections were assigned a trough target of 10 to 15 µg/mL, whereas severe infections, including those caused by MRSA, were assigned a trough target of 15 to 20 µg/mL, as per IDSA/ASHP guidelines. We first evaluated the relationship between the initial dose prescribed and the resultant trough level. Two additional variables were also analyzed: (1) the percentage of patients with an initial therapeutic

trough (PITT), as defined by the severity of infection and target trough combination above; and (2) the time to therapeutic trough (TTT), which represented the length of time needed to reach a therapeutic trough, including the time spent for a dose adjustment when needed.

Phase 2: Development of the Guidelines and Implementation of the Intervention

In phase 2, based on diagnostic data and baseline performance, we created standardized vancomycin dosing guidelines with the input of local subject matter experts. The guidelines proposed that patients with mild/moderate infections receive 15 mg/kg per dose every 6 hours (maximum: 750 mg/dose) and those with severe infections, including MRSA, receive 20 mg/kg per dose every 6 hours (maximum: 750 mg/dose). Goal troughs remained the same as detailed in phase 1. Monitoring parameters were also included in the guidelines. After additional refinement with frontline users, including nurses and pharmacists, and approval by our institution’s medication education safety and approval committee, the guidelines (Fig 1) were implemented on January 1, 2015. Implementation included dissemination to the pediatric inpatient units and the PICU and postings in the resident work rooms, nursing stations, pharmacy, and on the hospital’s central policies and procedures Web site. Residents and nurses were introduced to the guidelines at dedicated conferences and through periodic e-mail communications. House staff received laminated cards to attach to their identification badges to enable quick access to the guidelines when needed.

Phase 3: surveillance and Analysis

In phase 3, we conducted prospective postintervention active surveillance of vancomycin use over a 14-month period (January 2015 to February

e2 by guest on November 2, 2020www.aappublications.org/newsDownloaded from

PEDIATRICS Volume 139, number 6, June 2017 e3

FIGURe 1The MGHfC vancomycin guidelines (adapted from the original document for the purposes of this manuscript). BUN/Cr, blood urea nitrogen/creatinine; CA-pneumonia, community-acquired pneumonia; I/O, input/output; IV, intravenous; max, maximum.

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

MIlOSlAVSky et al

2016). All patients who received vancomycin were screened. The inclusion and the exclusion criteria were identical to those used in phase 1. Data abstraction was completed from the charts of all patients who met inclusion criteria. To monitor potential adverse effects of the guidelines in real time, 4 team members received daily vancomycin trough levels for pediatric patients from the previous 24 hours. When a supratherapeutic level was identified, a team member investigated the specific circumstances within 8 hours of the report, directly communicated with the patient’s clinical care team, and then discussed the case with the other vancomycin team members. All data abstracted in phase 3 were similarly analyzed as in phase 1.

statistical Analyses

Statistical analyses were done by using both standard statistics as well as QI methods. Simple descriptive statistics were used to characterize the pre- and postintervention study populations. One continuous variable (TTT) and 3 dichotomous variables (PITT, patients with first vancomycin trough at 10–20 µg/mL, and patients with vancomycin-related toxicity) were identified for clinical relevancy and compared in pre- and postguideline data sets. For continuous variables, diagnostics for normality were applied. The t test was used for normally distributed data sets, and the Mann–Whitney nonparametric test was used for data sets that did not pass normality testing. For each dichotomous variable, a 2 × 2 table was constructed, and odds ratios, confidence intervals (CIs), and P values were calculated by using the χ2 test. If ≥1 cell in a table had ≤5 measurements, the Fisher’s exact test was used instead of χ2, because it calculates P values with better accuracy for small sample sizes.

For this QI project, the process measure was the application of the

Massachusetts General Hospital for Children (MGHfC) vancomycin guidelines. The outcome measures were PITT, patients with first trough between 10 and 20 µg/Ml, and TTT. Vancomycin-related toxicities, including nephrotoxicity, were the balance measures. The quality control methods used for analyses included process control charts with 3-σ control limits and special cause rules based on the Institute for Healthcare Improvement.

We compared the preguideline patient population and the postguideline, compliant patient population. We also compared the preguideline population and all evaluable postguideline patients regardless of compliance with the guidelines. Noncompliance was defined as those patients who met inclusion criteria, but were prescribed vancomycin in doses and/or intervals different than those proposed by the guidelines, or patients who were prescribed vancomycin appropriately, but had incorrectly timed doses or incorrectly timed troughs.

In addition, we combined both pre- and postintervention data sets and calculated the means and 95% CIs of the initial troughs when the doses of 15 mg/kg per dose every 6 hours and 20 mg/kg per dose every 6 hours were used.

Standard statistical analyses were performed by using the Prism software package (version 7.02; GraphPad Software, Inc, La Jolla, CA) and a statistical process control chart was completed through QI Macros for Excel (KnowWare International, Inc, Denver, CO). Significance tests were all 2-tailed at P < .05.

ResUlTs

A total of 116 patients were included. In phase 1, 49 patients met inclusion criteria over the 4-year retrospective review period, out of a total of 506 patients screened

(9.7%). Patient accrual was hindered by the high number of patients who had a change in dose before initial trough measurement and/or incorrectly timed troughs. In this preintervention group, there was significant heterogeneity in the doses and intervals prescribed (Fig 2A) with an overall trend of higher total daily doses yielding higher average troughs (Fig 2B). This provided the rationale for recommending higher initial doses in the subsequent guidelines. In the postintervention phase, 127 patients out of 305 patients screened (41.6%) met inclusion criteria, but only 67 patients were treated according to the recommended guidelines, with an overall compliance rate of 52.8% (67 out of 127 patients) (Fig 3). Of the 60 noncompliant patients, only 8 had interpretable troughs.

The preguideline population and the postguideline, compliant patient population were comparable overall (Table 1). Younger patients predominated in both groups, along with boys. A large but comparable proportion of both groups were patients admitted to the PICU, likely reflective of the comparatively sicker population in need of vancomycin therapy while hospitalized. The proportion of patients who achieved a therapeutic trough during their hospitalization was not significantly different between both groups.

The impact of the intervention is illustrated in Table 2 and Fig 4. There was a significant increase in the percentage of PITT (6.1% vs 20.9%, P = .03) as well as a significant decrease in the TTT (2.78 days vs 1.56 days, P = .001) (Table 2). The percentage of patients with first trough between 10 and 20 µg/mL rose from 8.2% in phase 1 to 40.3% in phase 3 (P < .001) (Table 2), indicating a significant proportion of patients at or close to the therapeutic target. In the statistical process

e4 by guest on November 2, 2020www.aappublications.org/newsDownloaded from

PEDIATRICS Volume 139, number 6, June 2017 e5

FIGURe 2Prescribing and monitoring outcomes in the preintervention population. A, Distribution of dosing frequencies in the preintervention population. B, Relationship between initial dose and average initial trough in the preintervention population. a The actual doses are equal to or within 10% of the dose listed. Q6H, every 6 hours; Q8H, every 8 hours; Q12H, every 12 hours .

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

MIlOSlAVSky et al

control chart (XmR chart) (Fig 4), the baseline period revealed wide variability in TTT. Postintervention, all data points were within tighter control limits, indicating a process in more control with improved TTT.

When comparing the preguideline population (N = 49) to all postguideline patients who met inclusion criteria and had interpretable troughs (N = 75;

67 patients who were guideline compliant and 8 patients who were noncompliant and had interpretable troughs), a similar trend was noted. The percentage of patients with first trough between 10 and 20 µg/mL was improved by the guidelines (8.2% vs 37.3%, P < .001). There was a trend for improvement for percentage of PITT (6.1% vs 18.4%, P = .06). TTT and toxicity calculations were similar to those calculated

when preguideline and postguideline, compliant patients were compared, because the 8 noncompliant patients with interpretable troughs had no vancomycin-associated kidney injury and none achieved therapeutic levels while hospitalized.

When patients from both pre- and postintervention data sets were combined, the average initial trough was 7.49 µg/mL in 49 patients who

e6

FIGURe 3Flowchart of the postintervention patient population. a Overall compliance rate with the guidelines was 52.8% (67 patients out of 127 patients who met inclusion criteria). b Noncompliance was defined as those patients who met inclusion criteria but were prescribed vancomycin in doses and/or intervals different than those proposed by the guidelines, or patients who were prescribed vancomycin appropriately, but had incorrectly timed doses or incorrectly timed troughs.

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

PEDIATRICS Volume 139, number 6, June 2017

were dosed at 15 mg/kg per dose every 6 hours (95% CI: 6.45–8.39) and 12.7 µg/mL in 31 patients who received 20 mg/kg per dose every 6 hours (95% CI: 10.54–15.09).

Although limited by the relatively small numbers of patient encounters per group, the observed proportion of vancomycin-related toxicities was low in both study groups and unchanged by the intervention (Table 2). In each phase 1 and phase 3 patient cohorts, 3 patients developed vancomycin-related acute kidney injury, all of whom recovered.

DIscUssIOn

The most recent vancomycin guidelines1, 2 recommend dosing of 15 mg/kg every 6 to 12 hours to achieve goal troughs of 15 to 20 µg/mL for serious and invasive infections. The results of recent studies, however, suggest that it is difficult to reliably attain troughs in this range by using the recommended dose and interval.4, 6, 7 The principal goal of this QI project was to improve adherence to the national guidelines with timely and consistent attainment of the recommended trough levels through the use of

higher, illness severity-specific initial doses. Although previous research has suggested using higher doses, 4, 8, 9 this is the first study to implement this in pediatric clinical practice and prospectively analyze its impact.

The development of the MGHfC guidelines relied on 2 premises: higher initial daily doses and a fixed interval between doses. Higher dosing was supported by the preintervention results (Fig 2B), as well as by previous research.3, 4, 6, 7, 10 In studies using 15 mg/kg every 6 hours, only 6.76%4 or 13%7 had troughs between 15 and 20 µg/mL, and the average resultant trough was 10.7 µg/mL.6 Another retrospective review by Geerlof and Boucher3 found that only 31.7% of pediatric patients treated with 60 mg/kg per day had troughs between 10 and 20 µg/mL. Larger doses >60 mg/kg per day have therefore been proposed because low troughs may contribute to treatment failures and increased bacterial resistance.11 A dosing equation by Eiland et al8 predicted that, for patients with uncomplicated infections, 70 mg/kg per day should yield a trough of 10 µg/mL and 85 mg/kg per day should yield a trough of 15 µg/mL. Although cognizant of the potential risk of dose-related vancomycin nephrotoxicity, the aggregate of the above results, as well as ours, support the need to use higher vancomycin doses to meet the IDSA-recommended goal troughs of 15 to 20 µg/mL for serious infections.

The fixed interval of every 6 hours between doses was chosen for 2 reasons. First, it provided an earlier opportunity for trough measurement and dose adjustment as well as evaluation of toxicity in comparison with a dosing schedule of every 8 or 12 hours. Second, it minimized the number of variables in dose adjustments for frontline users by only allowing changes in individual dose versus potentially changing the dose and the interval. The doses

e7

TABle 1 Characteristics of the Preguideline and the Postguideline, Compliant Patient Populations

Preguideline Population (N = 49)

Postguideline, Compliant Population

(N = 67)

P

Mean age (y) 5.66 5.18 .83a

Age distribution, y, N (%) <2 20 (40.8) 27 (40.3) .96b

2–6 13 (26.5) 20 (29.8) .70b

6–12 6 (12.2) 7 (10.4) .76b

12–18 10 (20.4) 13 (19.4) .89b

Sex; N (%) Girl 17 (34.7) 30 (44.8) .27b

Boy 32 (65.3) 37 (55.2) .27b

Mean weight (kg) 25.29 20.57 .57a

Patients who were admitted to the PICU; N (%)

20 (40.8) 23 (34.3) .47b

Patients who achieved therapeutic trough; N (%)

18 (36.7) 31 (46.3) .40b

—, XX.a Mann–Whitney test.b χ2.

TABle 2 The Impact of the Vancomycin Guidelines on Clinically Relevant Variables Using Standard Statistics

Preguideline Population

(N = 49)

Postguideline, Compliant Population

(N = 67)

Relative Risk (Effect Size)

P

PITT, % 6.1 (N = 3) 20.9 (N = 14) 2.63 .03a, *

Patients with first trough 10–20 µg/ml, %

8.2 (N = 4) 40.3 (N = 27) 4.10 <.001a, *

TTT mean d (95% CI) 2.78b (1.99–3.56) 1.56c (1.22–1.89) N/A .001d, *

Patients with vancomycin-related toxicitye, %

6.1 (N = 3) 4.5 (N = 3) 0.84 .70d

PITT: 10–15 µg/ml for patients with mild/moderate infections and 15–20 µg/ml for patients with MRSA/severe infections. N/A, not applicable. a Fisher’s exact test.b In 18 patients who achieved a therapeutic tough during hospitalization.c In 31 patients who achieved a therapeutic tough during hospitalization.d Unpaired t test.e Excluding red man syndrome. All toxicities documented were vancomycin-related acute kidney injury.* P < .05.

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

MIlOSlAVSky et al

and interval used in our guidelines were ultimately devised to balance the higher doses needed for goal trough attainment and the potential risk of dose-related vancomycin nephrotoxicity.

Although the preintervention results demonstrated inconsistent and largely ineffective practices (Fig 2, Table 2), the postintervention analysis of patients compliant with the guidelines (N = 67) showed an in-control process (Fig 4) with a substantial improvement in trough measurements and a decrease in TTT by 29.3 hours (Table 2). When the preguideline population (N = 49) was compared with all postguideline patients who met inclusion criteria and had interpretable troughs (N = 75), similar results were noted. However, the percentage of PITT became only marginally significant (P = .06), essentially highlighting the

need for improved compliance with the guidelines. The intervention also allowed streamlining of practices with an effective study accrual of 67 patients out of 305 patients screened (22.0%) (Fig 3) compared with 49 patients out of 506 patients screened (9.7%) preintervention (P < .001).

Although the numbers of patients evaluated were relatively small in both study groups, we did not observe a significant increase in vancomycin-related toxicities. All documented toxicities were reversible kidney injury. The guidelines emphasize careful attention to fluid balance while on therapy and more frequent laboratory monitoring in ill patients or those with concomitant use of nephrotoxic agents. It is our opinion that more emphasis should be placed on ensuring optimal pharmacodynamic vancomycin

exposure to improve drug efficacy and avoid the development of resistance, rather than on the prevention of infrequent and largely reversible toxicities. These guidelines continue to be our hospital’s routine clinical practice and are also now being implemented at our community hospital sites.

Despite these noted improvements, the MGHfC guidelines failed to consistently produce therapeutic troughs in all patients. Higher or perhaps more age-specific doses are needed.12 It may also be that trough measurement is not the optimal approach to monitoring vancomycin efficacy and safety.13 There is poor correlation between vancomycin trough levels and clinical outcomes in the therapy of S. aureus infections.14 The AUC/MIC pharmacodynamic index is best predictive of vancomycin efficacy, 15– 17 and trough

e8

FIGURe 4The statistical process control chart analyzing the time to therapeutic trough pre- and postintervention. XmR chart, 3-σ control limits. Cl, control limit; lCl, lower control limit; UCl, upper control limit.

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

PEDIATRICS Volume 139, number 6, June 2017

measurements are generally used as a proxy measurement for AUC/MIC.7 The optimal vancomycin monitoring parameters, however, remain unclear. As additional studies examine the association between AUC/MIC and clinical and microbiological outcomes in pediatric populations (such as treatment outcomes and the development of resistance), it may be that AUC/MIC should replace trough measurements for vancomycin therapeutic monitoring.18, 19 What is clear, however, is that the emerging microbial resistance to vancomycin20 is likely associated not only with the intrinsic limitations of vancomycin, such as poor tissue penetration and relatively slow bacterial killing, but also with the considerable variability in prescribing practices.5 The use of standard guidelines such as ours would help streamline these practices.

Our study has several limitations. First, it has relatively small numbers and was conducted at a single clinical center, which limits its generalizability. However, as previously stated, several previous studies have found similar deficiencies in vancomycin practices based on retrospective analyses, 3 and, as a quality improvement project, these numbers should be sufficient to determine control limits and provide appropriate information regarding the stability of a process. A second limitation was the exclusion of patients with unpredictable volume of distribution, such as patients requiring vasopressor support, and patients with increased potential for nephrotoxicity, such as those with kidney disease, cystic fibrosis, and concomitant therapy with an aminoglycoside. This reduces

the study’s external validity, but we wanted to be particularly careful and avoid using higher vancomycin doses in these fragile patients with unstable pharmacokinetics. Notably, however, this was not a proxy for excluding sick children; more than a third of our subjects were in the PICU and many were intubated and sedated. The third limitation was the average compliance rate of 52.8% (Fig 3). Noncompliance was due to several factors, including incorrect dosing for weight, incorrectly timed doses, and inappropriately timed troughs (Fig 3), which are areas for improvement that we plan to target in the next Plan-Do-Study-Act cycle. Some factors contributing to noncompliance, however, are not modifiable, such as the use of premixed doses of antibiotics in critical areas of the hospital, including the emergency department and the oncology clinics, to facilitate expedited antibiotic therapy for sick patients. We have no immediate plans to change this practice. As we enter a new Plan-Do-Study-Act cycle, the areas of focus will be to improve the compliance rate by targeting modifiable factors and by integrating the guidelines into our newly introduced computer ordering system. Finally, we did not assess the pharmacoeconomic implications of our intervention or its impact on direct clinical or microbiological variables, but the variables we analyzed are credible proxies for direct outcomes.

cOnclUsIOns

The vancomycin prescribing guidelines suggested in this study offer a relatively simple and safe approach to better conform to the

IDSA and ASHP trough targets. The intervention was relatively low effort to implement at a minimum cost. In dynamic hospital environments, there are frequent opportunities for education and reinforcement of such policies, making our project sustainable and fully applicable to other institutions. Future areas of interest include the impact of these guidelines and the shortened TTT on direct clinical, microbiological, economic and safety outcomes. Other research efforts should evaluate the utility of other dosing schema in pediatric populations, such as loading doses or continuous infusions in comparison with intermittent doses, and the AUC/MIC methodology in comparison with trough measurements.

AcknOwleDGMenTs

We thank the MGHfC Quality and Safety Committee for their support of this work.

e9

FInAncIAl DIsclOsURe: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUnDInG: This study was supported by a Massachusetts General Hospital for Children quality and safety intramural grant.

POTenTIAl cOnFlIcT OF InTeResT: The authors have indicated they have no potential conflicts of interest to disclose.

ABBRevIATIOns

ASHP:  American Society of Health-System Pharmacists

AUC/MIC:  area under the curve/minimum inhibitory concentration

CI:  confidence intervalIDSA:  Infectious Diseases Society

of AmericaMGHfC:  Massachusetts General

Hospital for ChildrenMRSA:  methicillin-resistant

Staphylococcus aureusPITT:  patients with initial trough

at therapeutic levelQI:  quality improvementTTT:  time to therapeutic trough

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

MIlOSlAVSky et al

ReFeRences

1. Rybak M, lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists [published correction appears in Am J Health Syst Pharm. 2009;66(10):887]. Am J Health Syst Pharm. 2009;66(1):82–98

2. liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]. Clin Infect Dis. 2011;52(3):e18–55

3. Geerlof lM, Boucher J. Evaluation of vancomycin dosing and corresponding drug concentrations in pediatric patients. Hosp Pediatr. 2014;4(6):342–347

4. Durham SH, Simmons Ml, Mulherin DW, Foland JA. An evaluation of vancomycin dosing for complicated infections in pediatric patients. Hosp Pediatr. 2015;5(5):276–281

5. Gordon Cl, Thompson C, Carapetis JR, Turnidge J, kilburn C, Currie BJ. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012;31(12):1269–1271

6. Madigan T, Sieve RM, Graner kk, Banerjee R. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy. 2013;33(12):1264–1272

7. Hwang D, Chiu N-C, Chang l, et al. Vancomycin dosing and target attainment in children [published online ahead of print September 18, 2015]. J Microbiol Immunol Infect. doi: 10. 1016/ j. jmii. 2015. 08. 027

8. Eiland lS, English TM, Eiland EH III. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45(5):582–589

9. Eiland lS, Sonawane kB. Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients. J Pediatr Pharmacol Ther. 2014;19(3):182–188

10. Golenia BS, levine AR, Moawad IM, yeh DD, Arpino PA. Evaluation of a vancomycin dosing nomogram based on the modification of Diet in Renal Disease equation in intensive care unit patients. J Crit Care. 2013;28(5):710–716

11. kollef MH. limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45(suppl 3):S191–S195

12. Hoang J, Dersch-Mills D, Bresee l, kraft T, Vanderkooi OG. Achieving therapeutic vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014;67(6):416–422

13. Chhim RF, Arnold SR, lee kR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Pediatric Infect Dis Soc. 2013;2(3):259–262

14. Prybylski JP. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational

studies. Pharmacotherapy. 2015;35(10):889–898

15. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–1663

16. Song kH, kim HB, kim HS, et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2015;46(6):689–695

17. Britt NS, Patel N, Horvat RTSM, Steed ME. Vancomycin 24-hour area under the curve/minimum bactericidal concentration ratio as a novel predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2016;60(5):3070–3075

18. Brown Dl, lalla CD, Masselink AJ. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug. Ther Drug Monit. 2013;35(4):443–449

19. le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155–e163

20. Smith Tl, Pearson Ml, Wilcox kR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group. N Engl J Med. 1999;340(7):493–501

e10 by guest on November 2, 2020www.aappublications.org/newsDownloaded from

DOI: 10.1542/peds.2016-2423 originally published online May 11, 2017; 2017;139;Pediatrics 

Cummings and Chadi M. El SaleebyMolly Miloslavsky, Marjorie F. Galler, Iman Moawad, Janet Actis, Brian M.

Improvement InitiativeThe Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality

ServicesUpdated Information &

http://pediatrics.aappublications.org/content/139/6/e20162423including high resolution figures, can be found at:

Referenceshttp://pediatrics.aappublications.org/content/139/6/e20162423#BIBLThis article cites 20 articles, 5 of which you can access for free at:

Subspecialty Collections

bhttp://www.aappublications.org/cgi/collection/infectious_diseases_suInfectious Diseasesubhttp://www.aappublications.org/cgi/collection/quality_improvement_Quality Improvement_management_subhttp://www.aappublications.org/cgi/collection/administration:practiceAdministration/Practice Managementfollowing collection(s): This article, along with others on similar topics, appears in the

Permissions & Licensing

http://www.aappublications.org/site/misc/Permissions.xhtmlin its entirety can be found online at: Information about reproducing this article in parts (figures, tables) or

Reprintshttp://www.aappublications.org/site/misc/reprints.xhtmlInformation about ordering reprints can be found online:

by guest on November 2, 2020www.aappublications.org/newsDownloaded from

DOI: 10.1542/peds.2016-2423 originally published online May 11, 2017; 2017;139;Pediatrics 

Cummings and Chadi M. El SaleebyMolly Miloslavsky, Marjorie F. Galler, Iman Moawad, Janet Actis, Brian M.

Improvement InitiativeThe Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality

http://pediatrics.aappublications.org/content/139/6/e20162423located on the World Wide Web at:

The online version of this article, along with updated information and services, is

by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397. the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2017has been published continuously since 1948. Pediatrics is owned, published, and trademarked by Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it

by guest on November 2, 2020www.aappublications.org/newsDownloaded from